Irinotecan and temozolomide led to inferior clinical outcomes for patients with recurrent and primary refractory Ewing sarcoma, a multiarm trial found.
A chemotherapy regimen that is standard in the US for patients with Ewing sarcoma appeared to improve outcomes, a randomized phase 3 trial showed.
Patients with advanced sarcoma who developed immune-related adverse events after immune checkpoint blockade were more likely to have a clinical benefit.
Binimetinib plus imatinib in the frontline setting appeared to improve outcomes for patients with advanced gastrointestinal stromal tumor, warranting further study.
A phase 2 trial is under way to evaluate an investigational autologous T-cell product in patients with advanced synovial sarcoma as well as other tumor types.
A single-arm phase II clinical trial is underway to evaluate temozolomide and olaparib as a treatment combination for patients with advanced uterine leiomyosarcoma.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Histology-tailored neoadjuvant chemotherapy failed to show superiority compared with standard neoadjuvant chemotherapy in patients with high-risk STS.
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
This indication was granted accelerated approval based on overall response rate (ORR) and continued approval may be contingent upon confirmatory trial results.
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
A novel patient-centered approach aids the collection of research on a rare cancer.
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.